ArticleNature2026
Targeting FSP1 triggers ferroptosis in lung cancer.
Abstract read
In one paragraph
Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed.
- The rise of reducing reagent-resistant TfR1 dimer marks ferroptosis.Nature cell biology · 2026Article
- Ferroptosis and tumor microenvironment: orchestrating therapy resistance, immune evasion, and metastatic events.Medical oncology (Northwood, London, England) · 2026Review
- Diet-Induced Phospholipid Remodeling Dictates Ferroptosis Sensitivity and Tumorigenesis in the Pancreas.Cancer discovery · 2026Article
- Cuproptosis and ferroptosis: signal pathways, diseases and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Enhancement of Ferroptosis in Escape Variant Tumor Cells by IFNγ Derived from Antigen-Specific T Cells Controls Tumor with Heterogeneity.Cancer immunology research · 2026Article
- NRF2-CDH6-CEBPD axis suppresses ferroptosis and drives cisplatin resistance in non-small cell lung cancer.Journal of cell communication and signaling · 2026Article
- Ferroptotic propagation: from single-cell execution to tissue-scale death programs.Cell research · 2026Review
- Article
- Mechanisms underlying propagation of ferroptotic cell death.Nature cell biology · 2026Review
- Ferroptosis in skeletal muscle: from molecular mechanisms to therapeutic interventions.Journal of orthopaedic translation · 2026Review
- Ferroptosis: Newly Emerged Regulator for Human Disease.MedComm · 2026Review
- Regulation of lipid oxidation and ferroptosis by a tunable axis of vitamin E, high-density lipoprotein, and scavenger receptor class B type 1.The Journal of biological chemistry · 2026Article
- [Prognostic Models and Clinical Translation Prospects of Lung Cancer Based on Novel Cell Death Modes].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- An iron logic unites bacterial and cancer persister cells.Nature reviews. Molecular cell biology · 2026Article
- Iron-addicted colorectal cancers exploit heme-complex II axis to resist oxidative cell death.Cell metabolism · 2026Article
- Opposing roles of DGAT-mediated lipid droplet biogenesis in the regulation of ferroptosis sensitivity.The FEBS journal · 2026Article
- MK-4 Ameliorates Post-Ovulatory Aging of Mouse Oocytes by Alleviating Iron Metabolism Disorder-Induced Oxidative Stress.Molecular reproduction and development · 2026Article
- Multi-omics profiling unveils biological and clinical insights into pulmonary sarcomatoid carcinoma.Cell reports. Medicine · 2026Article
- RAS signaling at the crossroads of radioresistance and tumor immunity.Journal for immunotherapy of cancer · 2026Review
- Intrinsic polyunsaturated fatty acid synthesis capacity dictates ferroptosis sensitivity under restricted arachidonic acid availability.Cell death discovery · 2026Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
20 authors.
Katherine Wu *Department of Pathology, New York University Grossman School of Medicine, New York, NY, USA.ORCID 0000-0002-0472-0166
Alec J Vaughan *Department of Pathology, New York University Grossman School of Medicine, New York, NY, USA.
Jozef P BossowskiDepartment of Pathology, New York University Grossman School of Medicine, New York, NY, USA.
Yuan HaoDepartment of Pathology, New York University Grossman School of Medicine, New York, NY, USA.
Aikaterini ZiogouDepartment of Pathology, New York University Grossman School of Medicine, New York, NY, USA.ORCID 0009-0000-0028-6748
Seon Min KimCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea.
Tae Ha KimCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea.ORCID 0000-0001-5182-8578
Mari N NakamuraDepartment of Pathology, New York University Grossman School of Medicine, New York, NY, USA.
Ray PillaiDepartment of Pathology, New York University Grossman School of Medicine, New York, NY, USA.ORCID 0000-0002-8335-3463
Mariana ManciniDepartment of Pathology, New York University Grossman School of Medicine, New York, NY, USA.
Sahith RajalingamDepartment of Pathology, New York University Grossman School of Medicine, New York, NY, USA.
Mingqi HanPulmonary and Critical Care Medicine, David Geffen School of Medicine (DGSOM), University of California Los Angeles (UCLA), Los Angeles, CA, USA.ORCID 0000-0003-2070-5967
Toshitaka NakamuraInstitute of Metabolism and Cell Death, Molecular Targets and Therapeutics Center, Helmholtz Munich, Neuherberg, Germany.
Lidong WangMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Suckwoo ChungDepartment of Pathology, New York University Grossman School of Medicine, New York, NY, USA.
Diane SimeoneMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
David ShackelfordPulmonary and Critical Care Medicine, David Geffen School of Medicine (DGSOM), University of California Los Angeles (UCLA), Los Angeles, CA, USA.ORCID 0000-0002-8270-898X
Yun Pyo KangCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea.ORCID 0000-0002-1149-0880
Marcus ConradInstitute of Metabolism and Cell Death, Molecular Targets and Therapeutics Center, Helmholtz Munich, Neuherberg, Germany.ORCID 0000-0003-1140-5612
Thales PapagiannakopoulosDepartment of Pathology, New York University Grossman School of Medicine, New York, NY, USA. thales.papagiannakopoulos@nyulangone.org.ORCID 0000-0002-2251-1624
Funding
Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1MMedical Scientist Research Service AwardT32GM136573 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SULMAN, ERIK · 2020 to 2024
$6.8MIdentifying metabolic dependencies in genetic subtypes of KRAS-driven lung cancerR37CA222504 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PAPAGIANNAKOPOULOS, THALES · 2018 to 2024
$3.3MTraining Program in Cell BiologyT32GM136542 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SMITH, SUSAN · 2020 to 2024
$3.0MNovel approaches to target KEAP1 mutant tumorsR01CA283049 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Thales Papagiannakopoulos · 2024 to 2026
$2.0MInvestigating the therapeutic potential of a novel glutamine antagonist in KEAP1 mutant lung cancerR01CA262562 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Thales Papagiannakopoulos · 2024 to 2026
$2.0MUncovering Genotype Specific Vulnerabilities in KRAS Mutant Lung Cancer?R01CA227649 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PAPAGIANNAKOPOULOS, THALES · 2018 to 2022
$1.9MLinear Ion Trap - Quadrupole LC-MS SystemS10OD032292 · OD · WAYNE STATE UNIVERSITY · PI MADDIPATI, KRISHNARAO · 2022 to 2022
$592kTriple Quadrupole - Ion Trap Hybrid LC/MS/MS SystemS10RR027926 · NCRR · WAYNE STATE UNIVERSITY · PI MADDIPATI, KRISHNARAO · 2010 to 2010
$425kMultispectral imaging & analysis of intact tissue sections w/ the Perkin Elmer VectraS10OD021747 · OD · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LOOMIS, CYNTHIA A · 2016 to 2016
$359kDissecting the role of redox homeostasis and ferroptosis in lung cancerF30CA275258 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WU, KATHERINE · 2023 to 2025
$161kNCI NIH HHS F30 CA275258NCI NIH HHS P30 CA016087NCI NIH HHS R01 CA227649NCI NIH HHS R01 CA262562NCI NIH HHS R01 CA283049NCI NIH HHS R37 CA222504NCRR NIH HHS S10 RR027926NIGMS NIH HHS T32 GM136542NIGMS NIH HHS T32 GM136573NIH HHS S10 OD021747NIH HHS S10 OD032292
Abstract
Emerging evidence indicates that cancer cells are susceptible to ferroptosis, a form of cell death that is triggered by uncontrolled lipid peroxidation
Indexed as
FerroptosisLung NeoplasmsAdenocarcinomaAdenocarcinoma of LungAnimalsApoptosis Regulatory ProteinsCarcinogenesisCell Line, TumorDisease Models, AnimalFemaleHumansLipid PeroxidationMaleMiceMice, KnockoutOxidoreductasesApoptosis Regulatory Proteinsferroptosis suppressor protein 1, mouseOxidoreductasesPhospholipid Hydroperoxide Glutathione Peroxidase
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.